Two therapies were previously approved for NPC, including arimoclomol (Miplyffa; Zevra Therapeutics) in combination with miglustat.3 Neither has been shown to reduce the risk of death, and both carry age and weight restrictions that limit access for the youngest, most seriously affected patients.1 Adrabetadex, a mixture of 2-hydroxypropyl-β-cyclodextrin isomers, is designed to restore intracellular cholesterol trafficking, addressing the disease’s underlying defect.2 A trained health care provider administers it intrathecally every 2 weeks.1
An Externally Controlled Survival Analysis
The FDA evaluated survival in 36 patients with I-NPC treated with adrabetadex across 3 clinical studies (NCT02534844, NCT03643562, NCT04958642) and an expanded access program, compared with a matched external control group. Treatment was associated with a 55% reduction in the risk of death, with a median overall survival of 8.5 years vs 4.9 years in controls. The benefit was observed regardless of concomitant miglustat use, which is off-label in NPC.1
Safety Centers on Hearing
Permanent hearing impairment, ranging from mild to profound, has occurred with adrabetadex—including in patients whose hearing was normal before treatment. Baseline audiology, including pure tone audiometry, speech recognition, and tympanometry, is required. Hearing is retested 1 to 2 weeks after the first and second doses at each dosage level, before the next dose; once the dose is stable or at maximum, testing shifts to monthly, then every 12 months. The dose is not increased if testing shows impairment beyond set limits.2
Ataxia and fatigue carry separate warnings. Both typically emerge within days of a dose and have required hospitalization in severe cases. Other common adverse reactions include vomiting, back pain, headache, fever, diarrhea, nausea, and cough.1,2
What Pharmacists Should Watch
With biweekly intrathecal dosing at treatment sites, health-system and specialty pharmacists will be involved in every dosing cycle. Practical touchpoints include confirming that audiology results are in hand before titration, preparing caregivers for postdose unsteadiness and fall risk, and flagging when severe ataxia or fatigue warrants a call. Beren expects availability at sites nationwide in early December, with a family access program offering site coordination and out-of-pocket assistance for eligible patients.2
